This is an overview of the field of immuno-oncology and the various immuno-oncology classes. Immunooncology is one of the most promising and fastest growing areas of cancer research, as well as one of the most active areas in terms of licensing deals and acquisitions.
Expectations for cancer vaccines have diminished after multiple failures. In theory, a cancer vaccine treatment should be able to strengthen the immune response against a cancer and help to prevent it from recurring. In practice, a series of Phase III studies investigating cancer vaccines have failed to meet their primary endpoints, and the potential future role of this class has diminished with each trial failure.
What's included in this report? -Three fully transcribed key opinion leader interviews -Coverage of the key immuno-oncology targets include key clinical trial results and a summary of deals related to that class -10-year sales forecasts are included for Yervoy, Opdivo, Keytruda, MEDI4736, and RG7446 -Development focus map shows which targets are being investigated by each of the 63 companies with immuno-oncology drugs in development.
Key questions answered:
-What are the key immuno-oncology products in development? -What important clinical trial results have been reported for drugs in each immuno-oncology drug class? -What specific targets and therapy approaches are the developers in this field focusing on? -What factors could limit the commercial potential of immuno-oncology drugs in development? -What recent deals have taken place that are related to the field of immuno-oncology? 
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